Table 4.
Comparison between adverse events reported in literature as associated with treatment with Vismodegib and Sonidegib [33,34,36,37,39,40,41,42].
| Vismodegib | Sonidegib | |
|---|---|---|
| Meal | No interference | On empty stomach |
| Drug interactions | + (minor substrate of CYP2C9 and CYP3A4) | + (avoiding the CYP3A inhibitors) |
| AE G ≤ 2 | 43% | 54% |
| AE G ≥ 3 | 56% | 43% |
| Muscle spasms G ≥ 3 | 6% | 3% |
| Alopecia G ≤ 2 | 66% | 50% |
| Diarrhea G ≥ 3 | 3% | 1% |
| Weight loss G ≥ 3 | 9% | 5% |
| Fatigue G ≥ 3 | 5% | 1% |
| CK G ≤ 2 | NR | 24% |
| Dysgeusia G ≤ 2 | 56% | 44% |
| Nausea G ≤ 2 | 33% | 38% |
| ORR LABCC | 60% | 71% |
| ORR M BCC | 49% | 23% |
| DOR (median months) LABCC | 26 | 16 |
| DOR (median months) MBCC | 15 | 18 |
Legend. ORR, overall response rate; LABCC, locally advanced basal cell carcinoma; MBCC, metastatic BCC; AE, adverse events; DORs, duration of response. Toxicities were reported in BOLT study and ERIVANCE study according to CTCAE (common toxicities criteria adverse events). NR, not reported; CK, creatin kinases.